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Abstract: Epilepsy is a frequent, chronic disease demanding long-term medication with 
  antiepileptic drugs (AEDs). When slow release formulations of AEDs are used the chance of 
compliance and control of seizures is increased. Lamotrigine (LTG) is a broad spectrum antiepi-
leptic drug (AED), effective against both generalized and partial seizures. Its immediate-release 
formulation (LTG-IR) requires twice-daily dosing. In contrast, an extended-release formulation 
(LTG-XR) may be given once daily, providing a flatter dose-concentration curve with apparently 
lower maximum serum levels. Simplified dosing positively affects compliance and LTG-XR 
has a similar profile of efficacy and tolerability to LTG-IR. Rashes, including Stevens–Johnson 
syndrome, are the most serious adverse effect impacting 0.8% of pediatric patients. Thus, 
LTG-XR should be discontinued upon the appearance of rash.
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Introduction
Epilepsy is regarded as one of the most common neurological disorders affecting 
about 1% of the world’s population.1 There are about 20 to 70 new cases each year 
per 10,000 individuals. Interestingly, the lifetime chance of developing epilepsy is 
estimated from 3% to 5%.1
Epilepsy may be a consequence of genetic factors, brain tumors, trauma or infec-
tions, stroke, developmental disturbances (eg, cortical dysplasia), neurodegenerative 
diseases, malformations (eg, tuberous sclerosis, neurofibromatosis), or vascular 
malformations (eg, arteriovenosus malformations).2 According to the classification 
of the International League Against Epilepsy (ILAE), seizures are either partial or 
generalized. A partial, or focal, seizure is evident when its initial semiology and 
  electroencephalogram (EEG) manifestations are encountered in a specified brain 
region at the onset of a seizure. On the other hand, generalized seizures involve both 
cerebral hemispheres at the start of the convulsions.2
Management of epilepsy may be complicated by multiple epilepsy syndromes possess-
ing varied pharmacosensitivities and, moreover, by inter-individual differences regarding 
disposition of antiepileptic drugs (AEDs).3 In the past two decades, a considerable number 
of new AEDs have been introduced and presently there are more than 20 medications 
available. Consequently, there are many therapeutic options and antiepileptic therapy can 
be tailored according to the patient’s individual circumstances. However, numerous options 
may also lead to choosing inappropriate or suboptimal AEDs. For most seizures, there 
is generally no significant difference in AED efficacy and therefore other factors chiefly Neuropsychiatric Disease and Treatment 2010:6 146
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LTG.15 In this context, the maintenance daily dose of LTG 
may differ, depending on whether a patient is taking enzyme 
inducers or VPA. Generally, most of the newer AEDs have 
no impact on the activity of hepatic enzymes so they are not 
expected to affect pharmacokinetic parameters of LTG.16
Importance of extended-release 
formulations
Extended-release formulations assume converting immediate-
release drugs possessing short half-lives into drugs with 
pseudo-long half-lives. This procedure considerably reduces 
the number of daily doses to one or two. Moreover, almost 
constant drug serum concentrations may be maintained.3 
With IR formulations, the drug peak serum concentration 
may be associated with considerable adverse effects which 
can be avoided with XR drugs because the overall serum 
dose-concentration curve is flatter. Moreover, the flatter 
dose-concentration curve helps to avoid a drug trough level, 
which makes seizure control more efficient.3 Lastly, XR for-
mulations are associated with much better compliance as the 
dosing frequency is only one or two doses per day.3
Potential shortcomings of such formulations cannot 
be overlooked, however. For instance, a missed dose is 
more likely to provoke a seizure if an AED is prescribed 
once daily due to a rapid decline in AED serum concen-
tration.17 Therefore, better compliance may be actually 
  complicated by missing a dose. This problem may be over-
come by administering two doses a day for XR formulations 
approved for only once-daily dosing.17 At present, there are 
XR formulations for CBZ,3 PHT,3 VPA,3 and levetiracetam18 
and the United States Food and Drug Administration (FDA) 
has recently approved XR Lamotrigine (Lamictal® XR™; 
  GlaxoSmithKline, London, UK) as a once-a-day add-on 
therapy for partial onset seizures with or without secondary 
generalization in patients aged at least 13 years.19
LTG-IR was initially introduced in the form of adjunctive 
therapy in adult partial epilepsies and subsequently in chil-
dren above the age of 2 years, however, its efficacy has been 
shown down to one month of age.3 During clinical trials in 
adults this AED was applied in daily dosages of 200–500 mg. 
Trough serum concentrations of only 1–4 µg/mL were 
observed since, in most cases, LTG was added to enzyme-
inducing antiepileptic drugs (EIAEDs).3 It is remarkable that 
even serum concentrations of 15 µg/mL are generally well 
tolerated.3 LTG is also indicated against generalized seizures 
in Lennox–Gastaut syndrome and has been approved for 
conversion to monotherapy.3 Interestingly, LTG has been 
influence the appropriate drug selection. These factors are 
related to the epilepsy syndrome, seizure types, potential side 
effects, comorbid conditions, concomitant medications, and the 
age and gender of the patient. The choice of a given AED or 
combination should be guided by knowledge and familiarity 
with AEDs and their interactions.4 Some recommendations 
and guidelines (eg, American Academy of Neurology [AAN], 
European Medicines Agency [EMEA], National Institute for 
Health and Clinical Excellence [NICE], Scottish Intercol-
legiate Guidelines Network [SIGN]) exist for the proper use 
of AEDs.5,6 For instance, AAN evidence-based guidelines 
recommend lamotrigine, gabapentin, topiramate, tiagabine, 
oxcarbazepine, levetiracetam, and zonisamide for adjunctive 
treatment of partial adult epilepsy and lamotrigine, gabapentine, 




Lamotrigine (LTG) is a broad spectrum AED that effectively 
protects in the form of add-on therapy against partial seizures, 
the generalized seizures of Lennox–Gastaut syndrome, and 
primary generalized tonic-clonic seizures in adults and 
children aged at least 2 years. This AED is also approved 
for conversion to monotherapy in adults.7 LTG is available 
as an immediate-release formulation (LTG-IR) that under-
goes a rapid and almost complete absorption following oral 
administration, with peak plasma levels being recorded from 
1.3 to 4.7 h. The elimination half-life (t1/2) after a single 
oral dose is above 30 h and multiple doses of LTG lead to 
a considerable reduction of about 24 h.8 Glucuronidation 
in the liver by UGT1A4 is the main metabolic pathway for 
this AED9–11 and it is clear that AEDs significantly affect-
ing the activity of this enzyme may also distinctly modify 
pharmacokinetic parameters of LTG. For instance, carba-
mazepine (CBZ) and phenytoin (PHT) are strong inducers 
of UGT1A4 and their combined treatment with LTG results 
in a substantial increase in its systemic clearance.12,13 Also, 
enzyme inducers (ie, CBZ, PHT) are responsible for the 
significant reduction in the LTG’s elimination half-life from 
approximately 24 to 13 h.12,13 In contrast, valproate (VPA) 
as an inhibitor of glucuronidation has been documented to 
significantly reduce the clearance of LTG with a concomitant 
increase in its elimination half-life from approximately 
37 to 48 h.14 Moreover, LTG serum concentrations were 
significantly increased from 4.67 ± 3.66 (LTG monotherapy) 
to 9.56 ± 5.27 µg/mL in patients receiving both, VPA and Neuropsychiatric Disease and Treatment 2010:6 147
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found to be effective in treating bipolar disorder and neu-
ropathic pain syndromes.3,20 More studies are necessary to 
evaluate its possible efficacy in the treatment of Alzheimer’s 
disease and cocaine addiction.20
LTG-IR is recommended twice-daily in the form of mono-
therapy or add-on therapy with enzyme inducers. This dosing 
may be reduced to once-daily administration when LTG-IR 
is combined with VPA.8 Logically, a formulation providing 
therapeutic drug serum concentrations, given once a day, can 
positively affect compliance. LTG-XR, due to a special erod-
ing matrix, considerably reduces the rate of LTG release over 
12–15 h.3 An enteric coating additionally prevents LTG release 
which starts when a tablet passes to the duodenum.17
Pharmacokinetics of LTG-XR
In the Tompson et al Compass study,7 the main outcome 
of enrolling the epileptic patients to LTG-XR once-daily 
dosing as an add-on LTG formulation resulted in a slower 
rate of absorption and reduced fluctuations in this AED 
serum concentration, when compared to LTG-IR adminis-
tered twice a day. Steady-state concentration was achieved 
after two weeks of LTG-XR administration in patients who 
previously were given twice-daily LTG-IR for 14 days. 
The median time for the maximal serum concentration 
(Tmax) following an oral dose of LTG-XR was, in the period 
of 15–28 treatment days, 4–6 h in the group receiving 
EIAEDs (induced group), 6–10 h in the group on neutral 
AEDs (neutral group), and 9–11 h in patients prescribed 
VPA (inhibited group). It is noteworthy that the median 
Tmax for LTG-IR ranged from 1 to 1.5 h independently of 
the accompanying AEDs.7 Dose-normalized steady-state 
serum maximal concentrations (Cmax) of LTG were lower in 
patients on LTG-XR: 29% in the induced and 11% lower in 
the remaining two groups. On the other hand, steady-state 
LTG minimal concentrations (Cmin) were comparable to 
those found in patients on LTG-IR. The mean fluctuation 
indices in patients receiving LTG-XR were approximately 
27%–37% lower compared to the LTG-IR group.7
Efficacy and adverse effects  
of LTG-XR
Although the Compass study7 was mainly devoted to the 
comparison of pharmacokinetic parameters of LTG-IR and 
LTG-XR, the authors also recorded adverse effects. The 
patients (a total of 44 and aged at least 13 years) enrolled in 
this study experienced partial seizures (55%), generalized 
seizures (23%) or both generalized and partial seizures 
(23%). The mean seizure frequencies per week did not differ 
significantly in three phases of this study (baseline phase, 
LTG-IR twice-daily for two weeks with concomitant AEDs; 
XR treatment phase, LTG-XR once-daily with the AEDs 
for two weeks; and IR phase, switching back to twice-daily 
LTG-IR for one week) and were 1.8, 1.4, and 1.5, respec-
tively. The major adverse effect was headache which affected 
three out of 44 patients in the first phase (7%) and six out of 
38 patients in the second phase (16%). No headaches were 
reported in the third phase of this study. Other adverse effects 
(eg, vomiting, insomnia, nausea, tremor) were not observed 
in more than 3% of patients.7
The Armor study21 evaluated patients naïve to LTG, aged 
at least 13 years, and treated with one or two AEDs with an 
8-week baseline phase. Those who experienced eight or more 
partial seizures were randomized to groups on either once-
daily LTG-XR (118 patients) or placebo (121 patients), and 
both groups were taking the former antiepileptic treatment. 
The initial seven weeks corresponded to the escalation phase 
and the next 12 represented the maintenance phase. The total 
median reduction in the seizure frequency was 47% vs 24.5% 
for placebo with the respective results for the escalation and 
maintenance phases being 30% vs 16% and 58% vs 27%. 
Remarkably, 19% of patients (vs 5% for placebo) became 
seizure free during the maintenance phase and 44% vs 21% 
for placebo achieved at least a 50% reduction in their seizure 
frequency. As for the adverse effects, the most commonly 
reported were dizziness (19% vs 5% placebo), headache 
(16% vs 18%), somnolence (7% vs 4%), nausea (7% vs 2%), 
diarrhea (7% vs 4%), and nonserious rash (2% vs 1%). In 
no case was serious rash evident.21
Both studies cited above indicate that LTG-XR was effec-
tive against partial and generalized seizures with no serious 
adverse effects. Since the active substance of LTG-XR and 
LTG-IR is the same, there is no reason to assume that the 
efficacy of these formulations may differ. LTG has been 
documented to block voltage-dependent sodium channels 
and non-N-methyl-D-aspartate (NMDA) receptors along 
with inhibiting glutamate release, which probably determines 
its broad spectrum of activity.22,23 LTG-IR has been found 
to be effective against generalized epilepsy syndromes in 
non-controlled designs.3 This AED has also shown efficacy 
in the absence of childhood or juvenile myoclonic epilepsy.3 
However, myoclonus and myoclonic epilepsy in infancy may 
be worsened by the use of LTG-IR.3 Since in many cases LTG 
is prescribed as an adjunctive AED, the final outcome of a 
drug combination may be dependent upon the second AED 
in the combination. In the case of LTG its interactions with Neuropsychiatric Disease and Treatment 2010:6 148
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other AEDs yield all major types of interactions: synergy, 
additivity, and antagonism, both in terms of the anticonvulsant 
action and neurotoxicity. Preclinical data based upon the test 
of maximal electroshock in mice indicate that synergy was 
observed when LTG was combined with VPA, gabapentin, or 
topiramate.24,25 Neurotoxicity was antagonistic for LTG + VPA 
and LTG + topiramate, pointing to the best preclinical profile 
of these combinations.24 When LTG was co-administered with 
  gabapentin, there was no neurotoxicity for a 50% anticonvul-
sant effect of this combination.25 In contrast, an anticonvulsant 
antagonism was evident for the combined treatment of LTG + 
CBZ or oxcarbazepine, their respective neurotoxicities being 
additive and synergistic.24,26 Evidently, the preclinical data sug-
gest that combinations of LTG with CBZ or oxcarbazepine are 
to be avoided in clinical practice. There are also examples of 
additivity both in the convulsive and neurotoxic tests involv-
ing LTG + levetiracetam or retigabine.27,28 All preclinical 
data were verified with brain concentrations of AEDs and in 
no case was a pharmacokinetic interaction shown.24–28 The 
clinical reports are generally in line with the preclinical data. 
For instance, LTG monotherapy was found to be superior to 
LTG + CBZ in drug-refractory epilepsy29 and LTG + VPA or 
topiramate was evidently synergistic in epileptic patients.30 
Preclinical data on interactions of LTG with other AEDs are 
summarized in Table 1.
Werz3 reviewed the tolerability of LTG-IR and listed 
adverse effects which were found to be at least 3 percentage 
points higher in LTG-IR patients than in placebo patients 
and included: dizziness, diplopia , ataxia, nausea, blurred 
vision, somnolence, vomiting, abnormal coordination, 
tremor, insomnia, and rhinitis. Among these, ataxia, diplo-
pia, dizziness, and nausea were statistically more frequently 
associated with LTG. Rash occurred in 10% of treatment 
patients versus 5% in the placebo group. However, cases of 
rash requiring hospitalization did not exceed 0.3% (the total 
of 3071 patients) and those with Stevens–Johnson syndrome 
represented 0.1%. The initial dose of LTG and the rate of 
titration seem critical for the occurrence of rash as a positive 
correlation has been observed. For instance, the initial dose 
of 25 mg was associated with a rash incidence of ca 1%; 
for 50 mg, the incidence was approximately 9%; 100 mg, 
approximately 12%; and 200 mg, approximately 38%. When 
the fifth week of titration was considered, LTG in the dose of 
62.5 mg was associated with a 1.5% incidence of rash while 
that of 375 mg led to 12% rash incidence. A recommendation 
by the LTG manufacturer to reduce the initial titration rate 
considerably diminished the rash incidence, including serious 
cases. Noteworthy, due to this recommendation LTG-IR has 
proven, since 1993, to be comparable to other AEDs (CBZ, 
phenobarbital, PHT, or zonisamide) in terms of inducing 
rash problems. With regards to quality of life, approximately 
30% of patients reported tiredness and cognition problems, 
however, LTG seems to affect the quality of life much less 
than other AEDs such as CBZ, PHT, topiramate, and VPA.3
Now, there are recent data available on the tolerability 
of LTG-XR (LAMICTAL® XR™).31 In adjunctive therapy, 
this AED is associated with an incidence of rash in 0.3% 
of treated adults and 0.8%, including Stevens–Johnson 
syndrome, in pediatric patients (aged 2–16 years). In a group 
of 1983 pediatric patients treated with LTG-XR there was 
one death related to rash. Therefore, the drug should not be 
given to pediatric patients aged under 13 years. So far, the 
existing post-marketing experience has recorded isolated 
deaths related to toxic epidermal necrolysis or rash, but due 
to their low numbers the precise incidence rate is not known. 
Some unproven hypotheses exist that the risk of rash may be 
positively correlated with the combined treatment of LTG-XR 
with VPA and/or exceeding the recommended initial dose or 
dose escalation for LTG-XR. It is not practically possible to 
predict the evolution of rashes from benign to life-threatening 
which is why this AED needs to be discontinued immediately 
upon the appearance of rash. The only exception is if the rash 
is determined to be a nondrug-related episode.
Adverse effects of both immediate and extended-release 
LTG formulations are listed in Table 2. It can be seen that 
the XR formulation was considerably better tolerated. 
For instance, dizziness, diplopia, ataxia, and nausea were 
observed in 35% (vs 5% placebo), 25% (vs 6% placebo), 
20% (vs 6% placebo), and 19% (vs 9% placebo) respectively 
of patients treated with LTG-IR. By contrast occurrence of 
Table 1 Preclinical data on the interaction profile of lamotrigine (LTG) with conventional and newer antiepileptic drugs (AEDs) in 
electroconvulsions in mice
  CBZ24 GBP25 LEV27 OXC26 RET28 TPM24 VPA24
LTG ↓Add ↑ 0Add ↓Syn 0Add ↑Ant ↑Ant
Notes: All interactions in the seizure test were calculated by isobolography. Neurotoxicity was evaluated by an isobolographic analysis with the exception of LTG + GBP. In 
this case, neurotoxicity was estimated for the 50% anticonvulsant effect of the combined AEDs and there was no impairment of motor performance in the chimney test.
Abbreviations: CBZ, carbamazepine; GB, gabapentin; LEV, levetiracetam; OXC, oxcarbazepine; RET, retigabine; TPM, topiramate; VPA, valproate; ↑, synergy; 
0 = addition; ↓ = antagonism in the seizure test; Syn, synergy; Add, addition; Ant, antagonism in the neurotoxicity test (chimney test).Neuropsychiatric Disease and Treatment 2010:6 149
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Conclusions
Evidence indicates that treatment compliance is negatively 
correlated with the frequency of daily drug dosing. For 
instance, once-daily dosing is associated with 73%–87% 
  compliance while that of twice-daily dosing is 70%–81%, 
three times daily is 52%–77%, and four times daily is 
39%–42%.5 LTG-XR may therefore be considered a for-
mulation beneficial for increasing compliance, especially 
in patients with poor conformity to twice-daily LTG-IR.36 
This drug also provides a flatter drug-concentration curve 
which, by reducing the maximum LTG levels, is assumed to 
be better tolerated. The desired pharmacokinetic parameters 
for LTG-XR have been confirmed in the Compass study.7 
This study also provided evidence regarding the efficacy of 
LTG-XR against partial and generalized seizures and the 
overall tolerability of this AED. The authors are of opinion 
that switching directly from LTG-IR to LTG-XR requires 
the same total daily dose of LTG.7 Another double-blind and 
placebo-controlled study has found LTG-XR to be effective 
against partial seizures with a good tolerability profile.21
Usually, little attention is paid as to which AED LTG is added 
to in the form of adjunctive therapy with regards to final protection 
against seizure activity. The presented preclinical data24–28 along 
with clinical studies,29,30 clearly indicate that combinations of 
LTG + CBZ or oxcarbazepine should be avoided.
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